Multiple Myeloma Patients are ALL “Toxicity-Vulnerable”

Are you a “Toxicity-Vulnerable Multiple Myeloma Patient?” 

It isn’t just old people who are “vulnerable to chemotherapy toxicity.Everyone suffers collateral damage when they undergo chemotherapy. I’m not just talking about the short-term side effects that people associate with chemotherapy such as hair loss and nausea. I’m talking about heart, brain and nerve damage. Common side effects that the majority of multiple myeloma patients suffer from.

I know. I was first diagnosed with multiple myeloma when I was 36 back in 1994. I was strong and otherwise healthy. Yet the chemotherapy regimens I underwent during ’95-’96 left me with short, long-term and late stage side effects. Some of these side effects healed. Some didn’t. Some side effects got worse over time.

Practically speaking, MMers must think long-term. Studies show that achieving complete or very-good partial remission is not required for a long overall survival. Meaning your induction therapy is probably going to be the first chemo regimen of several over the next decade or two.

There is a solution. Evidence-based Integrative therapies to enhance the efficacy of your chemo. Evidence-based, anti-MM nutrition, supplementation and lifestyle therapies.

The article linked and excerpted below talks about a chemo regimen for newly diagnosed MMers called VCD-Lite that is effective but should be used only for older folks who are too frail to withstand higher doses of chemotherapy.

Multiple Myeloma at a glance. Click the image below-

Multiple Myeloma Mind Map

The solution is not rocket science. I’m not talking about some sort of “ancient Chinese secret.” The induction chemotherapy “VCD-Lite” discussed below combined with the Multiple Myeloma Cancer Coaching Program will mean effective MM management with a LOT LESS toxicity.

Have you been diagnosed with MM? What symptoms are you experiencing? Scroll down the page, post a question or a comment and I will reply to you ASAP. Click the link on the right side of the page to watch the free webinar about the MM CC Program.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients

“Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma…

“With the high and increasing proportion of patients with multiple myeloma being very old and/or otherwise vulnerable to chemotherapy toxicity, it is increasingly important to determine the best regimens for treating these patients, yet existing clinical studies largely miss that mark by focusing on younger, fitter patients,”

“The best regimens maximize the likelihood of multiple myeloma control, ie, efficacy, while minimizing risk of severe toxicity…

Meanwhile, regarding current clinical practice we recognize recent studies that have shown that induction regimens that incorporate both proteasome inhibitors and immunomodulatory agents are likely the emerging standard of care for newly diagnosed myeloma,” the researchers wrote. “As a result, off protocol we frequently employ the dose-reduced lenalidomide, bortezomib, dexamethasone (‘RVD-lite’) for patients willing to come for once weekly bortezomib.””

 

 

Posted in Newly Diagnosed, side effects ID and prevention Tagged with:

Non-Toxic Smoldering Multiple Myeloma (SMM) Therapies

Watching and Waiting for Smoldering Multiple Myeloma (SMM) Patients is Easier Said Than Done-

Pre-Myeloma is comprised of 3 diagnoses. MGUS and SMM are considered to be asymptomatic blood disorders. Though pre-myeloma patients are usually told to “watch and wait” there is more pressure on the SMM patient to act then an MGUS patient. The MGUS patient has a 1% chance of progressing to full-blown multiple myeloma. This is compared to the SMM patient who has a 10% chance of progressing to MM annually. Further, “high-risk SMM” has an even greater risk of progression to MM.

  • Single Bone Plasmacytoma (SBP)
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)

Pre-MM at a glance- click the image below-

MGUS png Mind Map

The challenge for the SMM patient is that his/her pre-myeloma will probably become full-blown multiple myeloma pretty soon. If the SMM patient is considered to be high-risk SMM then it is only a matter of time.

Fortunately there are evidence-based, non-toxic therapies for SBP, MGUS and SMM patient shown to reduce the risk of progression to frank MM.

The study linked and excerpted below cites intravenous vitamin C or ascorbic acid to selectively kill both MM and SMM cells in patients while leaving normal cells unharmed. Further, the evidence-based, non-toxic therapies outlined in the Pre-Myeloma Cancer Coaching Guides also 1) reduce the risk of MM, 2) enhance bone health 3) improve the mind-body health of newly diagnosed patients.

Please click the link on the right of the page to watch the free webinar that discusses the Pre-Myeloma Cancer Coaching Program.

PRE MM 3d Cover

Do you have either SBP, MGUS or SMM? Are you experiencing symptoms such as bone pain, anemia or kidney damage? Please scroll down the page, post a question or a comment and I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

” We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iron, leads to the formation of highly reactive oxygen species (ROS) resulting in cell death. PAA selectively kills CD138+ MM tumor cells derived from MM and smoldering MM (SMM) but not from monoclonal gammopathy undetermined significance (MGUS) patients…

In the 1970s, Cameron and Pauling reported that high doses of vitamin C increased survival of patients with cancer (Cameron and Pauling, 1976 ;  Cameron and Pauling, 1978). Recently, reports have shown that pharmacologically dosed ascorbic acid (PAA) 50–100 g…

Posted in Newly Diagnosed, non-conventional therapies, Pre-Myeloma

Multiple Myeloma Patients Need Cancer Coaching-

Newly-Diagnosed Multiple Myeloma Patients Don’t Know What They Don’t Know- MM CC Can Help-

If you were diagnosed with Multiple Myeloma (MM) would you know what to ask your oncologist? I believe that MMers don’t know what they don’t know. I think this because I didn’t know what to ask my oncologist when I was first diagnosed. Neither I nor my wife had even heard of a cancer called Multiple Myeloma when I was first diagnosed.

MM at a glance- click the image now-

Multiple Myeloma Mind Map

It took me years of living with MM before I began to understand not only MM as a cancer but understand oncology specifically and conventional medicine in general.

My name is David Emerson. I am a long-term MM survivor and MM cancer coach. I now know what MMers should ask their oncologists. In most cases I can encourage the MMer to ask the question as well as give the MMer the study that discusses the question.

And I know what MM patients probably don’t want to ask their oncologists. Whether you want to discuss an issue with your oncologist or just with me, I can help.

Scroll down the page, post a question or comment and I will reply to you ASAP.

David Emerson

MM Survivor

MM Cancer Coach

Director PeopleBeatingCancer

Coaching Program Gives Cancer Patients a VOICE in Their Care

“In his Values and Options in Cancer Care (VOICE) study, Dr Epstein and his group offered an in-office training course for physicians…In addition, the researchers trained coaches to help patients identify the most important questions to ask their oncologists during an upcoming office visit…

The results showed that the intervention resulted in clinically and statistically significant improvements in the primary physician-patient communication end point

“We found that the intervention actually did make a difference in terms of communication,” Dr Epstein said…

Patients were also coached to think about what they want their doctor to know about them, to better help their care. The prompt list offered these suggestions:

  • I want to know the pros (benefits) and cons (side effects) of the treatments I’m getting.
  • I can deal with the truth about my condition.
  • I don’t know what to tell my family.
  • I worry that I’m going to suffer.
  • I worry that if I stop treatment, you might not be my doctor anymore.
  • I hate being dependent on others.
  • I would rather not discuss how much longer I have left.
  • When the time comes, I’d prefer to die at home.
  • I am afraid of dying.”
Posted in Multiple Myeloma, Newly Diagnosed Tagged with:

MGUS Therapy-Continous, Metronomic, Effective and…Non-Toxic???

Where is it written that chemotherapy must be toxic to be effective against MGUS and SMM?

The definition of chemotherapy does NOT say that chemo has to cause collateral damage to kill cancer cells.  MGUS and SMM are considered to be asymptomatic blood-disorders. These two diagnoses are not cancer. If you don’t want to “watch and wait,” pursue evidence-based, non-toxic therapies to reduce the risk of MGUS/SMM from growing into multiple myeloma.

MGUS at a glance- click the image below now-

MGUS png Mind Map

My experience as a long-term myeloma survivor and MM Cancer Coach is that MGUS and SMM patients do not want to watch and wait for their blood disorder to become full-blown multiple myeloma. At the same time, newly diagnosed MGUS and SMMers don’t want to live through toxic chemotherapy with all of the side effects.

The answer is evidence-based, non-conventional therapies that research has shown will reduce your risk of progression to multiple myeloma.

To learn more about the Pre-Myeloma Cancer Coaching Program scroll down the page, post a question or a comment and I will reply to you ASAP.

Thanks,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic

“The words ‘side effect’ usually evoke a mixture of fear and anxiety in cancer patients receiving chemotherapy…

Polverini’s group first reported anti-angiogenic effects mediated by conventional cytotoxic anticancer drugs as long ago as 15 years, and since then most common anticancer chemotherapeutic agents, belonging to all major classes, have been shown to be capable of inhibiting angiogenesis [2]. This prompted George Sledge and colleagues recently to suggest the notion of ‘redefining’ chemotherapeutic drugs as anti-angiogenics…

What would be the advantage of using chemotherapeutics as possible angiogenesis inhibitors?… Thus, the hypothetical beneficial anti-angiogenic side effect of chemotherapy would seem negligible, or minimal, at best…

This method of administrating chemotherapy was dubbed ‘anti-angiogenic chemotherapy’ by Browder et al. [8] or ‘metronomic’ dosing by Hanahan et al. [9]; the latter term implies regular, frequent administration of drug, which requires lower doses to be used

 

 

Posted in Multiple Myeloma, non-conventional therapies, nutrition, Pre-Myeloma Tagged with:

ASCT Now or Later? Makes No Difference in Multiple Myeloma

Do you care more about how long you live (OS) or how long your multiple myeloma is in remission (PFS)?

While there is no guarantee of either, you are trying to choose between therapies based on averages. The articles linked an excerpted below speak to one of the most frequently asked questions I hear from newly diagnosed myeloma patients. “Should I have my autologous stem cell transplant now or should I wait?”

I believe that if newly-diagnosed multiple myeloma patients are not going to sacrifice overall survival by waiting  then they should wait.

Multiple Myeloma at a glance- click the image below:

Multiple Myeloma Mind Map

Many patients tell me that their oncologists are pushing for an ASCT now but they want to wait. The articles below answer an important question. There is NO difference based on your overall survival aka length of life.

And make no mistake. An autologous stem cell transplant is high-dose chemotherapy and is very toxic. When I had my ASCT at 36, the procedure  left me with a host of short, long-term and late stage side effects. Novel therapies such as Revlimid, Velcade, etc. have questioned the benefit of autologous stem cell transplantation for multiple myeloma patients.

Progression-Free Survival- The time for your multiple myeloma to progress from the date of your ASCT.

Overall Survival- The is how long MM patients live. Length of life. PFS measures time to when the cancer begins growing again after therapy.

In addition to the long and growing list of FDA-approved chemotherapy regimens that are cytotoxic to multiple myeloma, there is also a long and growing list of evidence-based, non-toxic therapies that are cytotoxic to multiple myeloma. I have lived in complete remission from my MM since ’99 by living an evidence-based, anti-MM lifestyle through nutrition, supplementation, bone health, etc.

I am both a long-term MM survivor and MM Cancer Coach. Click the link on the right of the page now to watch a free webinar about the Multiple Myeloma Cancer Coaching Program that I designed and created based on my 22 plus years living with MM.

Have you been diagnosed with multiple myeloma? What stage? Are you experiencing any symptoms such as bone pain, anemia or kidney damage?

Scroll down the page to post a question or comment. Thanks and hang in there.

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Early Or Late Stem Cell Transplantation For Myeloma? New Study Finds Both Strategies Yield Similar Overall Survival

“Results from a retrospective study show that delaying stem cell trans­plan­ta­tion following initial therapy may result in shorter progression-free survival following transplantation compared to transplantation soon after diagnosis.

However, the results also show that the timing of transplantation does not significantly impact overall survival…

Over the past 15 years, however, studies have shown that novel anti-myeloma agents – such as thalidomide(Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib) – extend the progression-free and overall survival of myeloma patients.  Due to the efficacy and high tolerability of the novel agents, many myeloma patients in recent years have been choosing to delay or forego stem cell transplantation…”

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

” In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies.”

Posted in Multiple Myeloma, side effects ID and prevention Tagged with:

CR or VGPR Makes NO Difference in Newly Diagnosed Multiple Myeloma

Complete Response (CR) or Very Good Partial Response (VGPR) In Newly Diagnosed Multiple Myeloma Makes NO Difference in Overall Survival. None. 

It would be logical to think that a complete response or MDR status translated into a long overall survival. I know I thought this when I had my autologous stem cell transplant. According to the two studies linked and excerpted below, I was wrong to think this.

Click the image below-

Multiple Myeloma Mind Map

Please don’t misunderstand me. Yes, a complete response is a positive indicator for a long overall-survival. But the opposite is not true. Not achieving a CR does not mean that you will not live a long OS. I had my autologous stem cell transplant in 12/95, relapsed about a year later and here I am writing this blog post 22 plus years later.

Or as Dr. Rajkumar (MM specialist) put it:

“It is one thing to say that achievement of complete response is a prognostic marker, but quite another to take that to mean we need to treat patients until they reach complete response.”

22 plus years of surviving MM and coaching MM patients had taught me that the key to living a long-overall survival in MM is to use the best of both conventional FDA approved MM and combine it with the best of non-conventional, evidence-based MM therapies to manage your MM. It is not about CR, VGPR or MDR.

It is about quality of life (QOL) and overall survival (OS).

Have you been diagnosed with multiple myeloma? If so, what stage? What symptoms are you experiencing? Bone pain? Anemia? Kidney damage?

Please scroll down the page, post a question or a comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Long-term MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma

“There was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in patients with newly diagnosed multiple myeloma, according to the results of a meta-regression analysis published recently in the European Journal of Hematology…

“We explored the relationship between response to initial treatment and survival in patients with newly diagnosed multiple myeloma, based on data from 63 randomized clinical trials”…

Meta-regression analyses failed to demonstrate any association between CR or (CR or VGPR) with either overall survival or progression-free survival both in patients receiving autologous stem cell transplant [ASCT] and in non-ASCT patients.”

Should Myeloma Patients Panic If They Do Not Achieve A Complete Response?

“Of course, the cause of my worry is not that patients have not achieved the magical complete re­sponse or minimal residual disease-negative status, but at how mis­in­ter­pre­ta­tion of data can lead to needless concern, unnecessary chemo­ther­a­py, increased side effects and cost of care, and even harm

Multiple myeloma is a remarkably heterogeneous disease; the outcomes vary dramatically depending on the patient’s chromosomal abnormalities. The type of myeloma one patient has may be completely different than the myeloma another patient has; it may not even be the same disease….”

 

Posted in Multiple Myeloma, Newly Diagnosed Tagged with:

MGUS, IP6 and Inositol

Can MGUS Patients Prevent full-blown MM with IP6 and Inositol? Jim Thinks So-

I believe that I have remained in complete remission from my end-stage Multiple Myeloma since ’99 by living an evidence-based, non-toxic, anti-MM lifestyle. Supplementation factors heavily into my anti-MM lifestyle.

So I don’t think preventing a diagnosis of full-blown MM after a diagnosis of either MGUS or SMM is a stretch. The research however, is thin when it comes to IP6, Inositol and pre-malignant blood cancers such as MGUS and SMM.

Have you been diagnosed with MGUS or SMM? Scroll down the page and ask me a question. Thanks.

MGUS at a glance- click the image below now-

MGUS png Mind Map

David Emerson

  • MM Survivor,
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Protection against cancer by dietary IP6 and inositol.

“For a long time IP(6) has been recognized as a natural antioxidant. Recently IP(6) has received much attention for its role in cancer prevention and control of experimental tumor growth, progression, and metastasis…

A striking anticancer action of IP(6) was demonstrated in different experimental models. In addition to reducing cell proliferation, IP(6) also induces differentiation of malignant cells. Enhanced immunity and antioxidant properties also contribute to tumor cell destruction.”

Jim’s MGUS Survivor Story-

When I started taking IP6 my IGM number went down.  When I cut IP6 intake in half, my IGM jumped by 20%.  Then when I started IP6 again, my numbers again trended downward.

In fact I’m doing so well that my Hematologist wants to start seeing me every 2 years instead of 6 months or a year.

Also, my globulins are now well within limits.  It was my globulins that had exceeded the upper limit which caused my doctor to order more blood tests and then further blood tests, ordered by my hematologist, that determined that I had MGUS.

I can relate to the fear you must have had when you were first diagnosed with multiple myeloma.  After my family physician did a couple other tests to determine there was something wrong, I thought I had MM.  And I didn’t see a hematologist for 3 months so for those three months, I thought I had 3 -5 years left to live.  That was the most horrible time of my life!  It felt like the rest of society (the living) were taking a fork in the road, all joyful and happy, leaving me behind.  Absolutely frightening.  I was so relieved with an MGUS diagnosis.  So I can’t imagine what you and other MM patients have gone through.

Now that my numbers are trending down, I have little fear.  And my hematologist thinks I’m doing good enough to go to 2 year visits instead of 6 months or a year.

Diagnosed with MGUS May, 2013

MY IGM numbers are as follows:

The upper normal limit  is 300

3/1/2013_______ 733

4/1/2013 started supplements of curcumin and IP6.

10/4/2013_______ 760_______ +4%
3/12/2014_______ 714_______ -6%
10/10/2014_______ 663_______ -7%

12 oct 2014 — Cut IP6 in half

4/1/2015_______ 797_______ +20%!

5 Apr 2015 —-  Ip6 back to 8

10/8/2015_______ 806_______ +1%
4/24/2016_______ 736_______ -9%
10/18/2016_______ 756_______ +3%

Notice that 20% jump on Apr 1, 2015?  That was 6 months after cutting IP6 in half. I was doing so well that after my blood test in Oct 2014, I cut the Ip6 in half because I was tired of taking so many pills.  I also take curcumin and continued to take 4 grams of that a day because there is more research for curcumin and even double-blind studies on it.  As far as I can tell, IP6 is only researched by Dr Shamsuddin of the University of Maryland, so far less research and only on rodents.

Globulins also show impact of dropping IP6.

Upper limit for Globulins is 3.5.

Date
1/1/2008_______ 3.3
11/4/2011_______ 3.3
2/4/2013_______ 3.7
10/4/2013_______3.5
3/12/2014_______ 2.8
10/10/2014_______ 3.3
4/1/2015_______ 3.6

4/28/2016_______ 3.1

Unfortunately, there really needs to be more data.  That 20% jump could have happened whether I was taking IP6 or not.  But, in general, my numbers seem to be steady or trend downward when I’m taking 8 grams or more of IP6/inositol.

What I take for supplements:
4 Dr’s Best Curcumin with BioPerine 1000mg

8 Ip-6& Inositol – 800mg of ip-6, 220mg of inositol.

I use either Cell Forte’s IP6 & Inositol or IP6 Gold.  The IP6 Gold is produced by the researcher Dr. Shamsuddin from the University of Maryland.  His University research paper on IP6 led me to take IP6.  However, his IP6 is twice as much as Cell Forte’s and Cell Forte’s ingredient list matches his.

Speaking of research:  When I do research, I always use Google’s “site:” feature to limit all research to sites ending in “.edu”.  So I add “site:.edu” to all my research on alternative cancer cures.  That way I only get university research papers and avoid snake oil sites.  Doing that type of search produces research papers and you need to be able to understand statistics and Latin etymology but at least you avoid scammer sites.

Posted in non-conventional therapies, Pre-Myeloma Tagged with:

Low Dose, Metronomic Therapy is the Key in Multiple Myeloma

It’s Not New and it is not an emerging concept in cancer treatment but this delivery system does Improve Outcomes and Eliminates Toxicity in Multiple Myeloma Treatment-

Where does it say that chemotherapy must be toxic? Nowhere. That’s my point. Historically speaking, yes, chemotherapy regimens are poisons that cause collateral damage aka side-effects. But chemo is not toxic by definition.

Further, chemotherapy is not tied to any single dosing regimen. Sure, most chemotherapy regimens specify timing such as each course being given every few weeks. But again, the timing of doses is not defined.

MM at a glance- click the image below-

Multiple Myeloma Mind Map

Low-dose Revlimid (lenalidomide) given daily has become standard-of-care in multiple myeloma treatment. The main problem with low-dose Revlimid maintenance therapy is the increased risk of second cancers. A treatment-related secondary cancer.  Even low doses of toxic chemo can cause more cancer.

The solution? Low-dose, metronomic, maintenance therapy that is cytotoxic to multiple myeloma but is NON-toxic. I have remained in complete remission from my MM since 4/99 with the help of non-toxic, low-dose maintenance and metronomic therapies.

I am a long-term MMer and MM Cancer Coach. The MM CC program incorporates the evidence-based info and therapies below:

  1. Listing of the most successful MM specialists and hospitals
  2. Dozens of foods that starve MM (anti-MM) foods
  3. More than 15 integrative therapies that synergize with five common MM chemotherapy regimens,
  4. Over a dozen evidence-based mind-body therapies,
  5. Detoxification therapies,
  6. Both conventional and non-conventional bone health therapies
  7. Review and links to more than 20 online MM support groups
  8. Studies reviewing Cannabis/CBD as integrative MM therapy, pain therapy and stand-alone MM therapy-

mm-guides-image

Whether you are debating treatment options, currently undergoing treatment and experiencing painful side effects, or trying to figure out how to stay in remission, I want to share what I’ve learned from 22 years of full remission from Multiple Myeloma.

To learn more about MM Cancer Coaching watch the video linked on the right side of the page or scroll down the page and post a question or a comment. I will reply to you ASAP.

 

Thanks,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCance

Important advance made with new approach to ‘control’ cancer, not eliminate it

“Researchers have created a new drug delivery system that could improve the effectiveness of an emerging concept in cancer treatment — to dramatically slow and control tumors on a long-term, sustained basis, not necessarily aiming for their complete elimination…

The approach, called a “metronomic dosage regimen,” uses significantly lower doses of chemotherapeutic drugs but at more frequent time intervals. This would have multiple goals of killing cancer cells, creating a hostile biological environment for their growth, reducing toxicity from the drug regimen and avoiding the development of resistance to the cancer drugs being used…

 

Posted in Multiple Myeloma, non-conventional therapies Tagged with:

Diagnostic Testing for MGUS

Whether you “watch and wait” or undergo non-toxic MGUS therapies, regular diagnostic testing is now a part of your life

You’ve been diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and you are trying to wrap your brain around this diagnosis. It is an asymptomatic “blood disorder” yet it can become a full-blown diagnosis of an incurable blood cancer called multiple myeloma.

My experience as a long-term cancer survivor is that the more you the patient, learn about your diagnosis,  the more in control you will become.

Click the mind map below to learn more about MGUS-

MGUS png Mind Map

This may sound odd but from my perspective  you are in a kind of a cancer sweet spot. By this I mean that your diagnosis should motivate you to make an effort to remain PRE-MM. And you can be certain you are pre-MM or MGUS only through diagnostic testing your blood, marrow and bones.

MGUS at a glance-

Frankly, regular testing is a small price to pay considering the downside risks of your MGUS becoming Multiple Myeloma. The diagnostic testing linked below will  explanation of some of the tests you will have short and/or long term.

An external file that holds a picture, illustration, etc. Object name is 13244_2016_492_Fig1_HTML.jpg

If you do not want to “watch and wait” to see if your MGUS/SMM progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.

Consider MGUS Therapies such as:

  1. non-toxic, cytotoxic/apoptotic supplements,
  2. foods that starve MGUS/SMM and MM
  3. evidence-based mind-body therapies,
  4. detoxification therapies,
  5. Non-conventional bone health therapies
  6. Cannabis/CBD/THC oil

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Blood-

“MGUS is usually detected during blood tests for another condition, such as a certain nerve disorder (peripheral neuropathy). The blood tests can show abnormal proteins as well as unusual amounts of normal proteins. If your doctor detects monoclonal gammopathy, further testing may be recommended to determine which M protein your body is making and how much is being made…”

Serum Protein Electrophoresis 

“Serum protein electrophoresis (SPEP) is an easy, inexpensive method of separating proteins based on their net charge, size, and shape…”

Serum free light-chain measurement

Immunoglobulin light chains that are circulating in serum in a free (unbound) state are called free light chains (FLCs). Measurement of the serum level of FLCs became practical as a clinical blood test in recent decades..”

Imaging tests

“Multiple myeloma is the most common primary malignant neoplasm of the skeletal system. The disease is a malignancy of plasma cells. Clinical definitions of the various myeloma subtypes have been updated as have the imaging definitions of what constitutes bone marrow disease and individual bony involvement..”

Bone Marrow Biopsy

“Our findings suggest that reports on bone biopsies should include in addition to the number of plasma cells, the pattern of plasma cell infiltration and the presence or absence of multiple lymphoid nodules…”

 

Posted in Newly Diagnosed, Pre-Myeloma Tagged with:

MGUS and SMM Risk of Progression to Multiple Myeloma

MGUS, SMM Risk of Progression is Where the Rubber Meets the Road!

Even if you have been diagnosed with either MGUS or SMM you may not have the diagnostic information about your pre-multiple myeloma to be able to determine your risk of progression to MM.

And even if you are able to determine your risk of progression to MM I believe that evidence-based, non-toxic therapies can reduce your risk of progression to MM. Please understand, I did everything my oncologist told me to do and I still relapsed and reached end-stage MM. Back in the fall of 1997. So I am cynical about conventional oncology. Especially where blood cancers are concerned.

Hi. My name is David Emerson. I am a long-term MM survivor and MM Cancer Coach. Welcome to PeopleBeatingCancer.org.

However, I do believe that having a thorough diagnosis and regular testing is critical for anyone diagnosed with pre-MM.

Image result for photo of blood cancer progression

MGUS at a glance- click the illustration below:

MGUS png Mind Map

Image result for photo of cancer progression

If you do not want to “watch and wait” to see if your MGUS/SMM progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.

Consider MGUS Therapies such as:

  1. non-toxic, cytotoxic/apoptotic supplements,
  2. foods that starve MGUS/SMM and MM
  3. evidence-based mind-body therapies,
  4. detoxification therapies,
  5. Non-conventional bone health therapies
  6. Cannabis/CBD/THC oil

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

“Predicting progression with current clinical risk models-

The Mayo Clinic risk stratification model for MGUS identifies 3 major risk factors for progression:

  • non-IgG isotype,
  • serum M-protein concentration > 1.5 g/dL, and
  • a skewed FLC-ratio (normal reference: 0.26-1.65).19

At 20 years of follow-up, absolute risk of progression for MGUS patients with 0, 1, 2, and 3 risk factors is

  • 5%,
  • 21%,
  • 37%, and
  • 58%, respectively (Table 2).19

For SMM, risk factors for progression include

  • bone marrow plasma cells > 10%,
  • serum M-protein concentration > 3 g/dL, and
  • a skewed FLC-ratio (normal reference: 0.125-8.0)

Cumulative risk of progression at 10 years for SMM patients with 1, 2, and 3 risk factors is:

  • 50%,
  • 65%, and
  • 84%, respectively (Table 2).20
Posted in non-conventional therapies, Pre-Myeloma Tagged with:
side-widget-mm-webinar-image